Bruker Announces Key Innovations for Multiplexed Spatial Proteomics and Unbiased Multiomic Imaging for Cancer Research
12 April 2022 - 12:24AM
Business Wire
- Bruker launches novel MALDI HiPLEX-IHC tissue imaging
solution for timsTOF fleX using AmberGen’s HiPLEX-IHC peptide code
antibody probes, combined with unbiased lipidomics, glycomics and
metabolomics tissue imaging
- New Canopy CellScape™ single cell, highly quantitative
spatial proteomic ChipCytometry™ platform features fully automated
iterative staining using open-source antibodies for virtually
unlimited immuno-oncology marker analysis on whole tissue sections
for TME and metastasis research
- For cancer cell-line assays and biopsy proteomics research,
dia-PASEF® on the timsTOF 4D platform can identify up to 13,000
proteins with 1% FDR (false discovery rate); identifies and
quantifies more than 8000 proteins in 35 minutes from ultra-deep
libraries; over 25% more phosphopeptides identified using novel
TIMScore algorithm
- Novel timsTOF SCP platform enables unbiased single cell
proteomics research, an essential complement to sc-RNA-seq for
spatial biology cancer research
- Unique high-throughput timsTOF Pro 2 platform enables liquid
biopsy biomarker research with various unbiased and deep plasma
proteomics and PTM methods
At the AACR Annual Meeting 2022, Bruker Corporation (Nasdaq:
BRKR) launched and exhibited unique and novel capabilities for
spatial multiomics, single-cell proteomics, and cell-line, tissue
and plasma proteomics cancer research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220411005644/en/
Sagittal mouse brain section showing
MALDI HiPLEX IHC mass tagged antibody locations in fresh frozen
tissue overlayed with an unbiased small molecule image showing the
presence of ganglioside and sulfatide lipids. The lower inset
spectrum shows detected masses of the photocleaved peptide labels.
(Photo: Business Wire)
Following up on Bruker’s recent strategic investment in AmberGen
Inc., Bruker is announcing a partnership for the application of
Ambergen Miralys™ peptide-code antibody kits for the Bruker timsTOF
flex novel MALDI HiPLEX-IHC workflow for targeted protein
expression profiling in tissue. By combining peptide-code
mass-reporting antibody probes for protein recognition with
Bruker’s comprehensive MALDI imaging workflows, researchers can
produce highly multiplexed images of target proteins in a wide
field-of-view up to a standard slide.
Bruker’s timsTOF fleX platform integrates MALDI HiPLEX-IHC
protein mapping with unbiased small molecule imaging (lipids,
glycans, metabolites, xenobiotics) from the same tissue section, a
new and unique multiomics capability for cancer cell-line, tissue
and TME imaging research from fresh frozen or formalin-fixed
paraffin-embedded (FFPE) sections.
Dr. Michael L. Easterling, Bruker Director of Imaging Life
Sciences Mass Spectrometry, commented: “Spatial protein expression
mapping can elucidate processes in immuno-oncology, and in TME and
metastasis research. The MALDI HiPLEX IHC workflow based on
AmberGen’s peptide-encoded antibody panels provides targeted
protein localization and adds the capability to map important
lipids, glycan and metabolite markers on the same tissue
section.
Additionally, Bruker demonstrated the new CellScapeTM
instrument for high-precision targeted spatial proteomics, recently
launched by their Canopy Biosciences division. Canopy Biosciences’
CellScape is the latest generation ChipCytometryTM instrument,
which enables high-plex spatial imaging and quantification of
protein biomarkers in a wide variety of sample types with
single-cell and sub-cellular resolution. CellScape further improves
spatial resolution, offers up to 8x higher throughput, and walkaway
automation. CellScape is unique for quantitative biology with 8-log
extremely high dynamic range (HDR) imaging to quantify both low and
high expressing proteins in the same sample, solving a key
challenge inherent in high-plex imaging. Applications in cancer
biology are abundant and include spatial phenotyping of the diverse
tumor and immune cell types in the tumor microenvironment
(TME).
Canopy also featured their Spatial Immune Profiling kits
for the ChipCytometry platform. The Spatial Immune Profiling kit is
a quantitative, multiplexed assay for FFPE tissues developed to
provide ready-to-use pre-validated antibody reagents for
ChipCytometry researchers, e.g., for immuno-oncology. The kits
enable researchers to skip assay development and move straight into
performing their translational and clinical research assays.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220411005644/en/
Media Contact Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E: petra.scheffer@bruker.com
Investor Relations Contact Justin Ward Sr. Director Investor
Relations & Corp Development T: +1 (978) 663–3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024